Medios AG ( (MEDOF) ) has released its Q2 earnings. Here is a breakdown of the information Medios AG presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Medios AG is a leading provider of Specialty Pharma Solutions in Europe, focusing on pharmaceutical supply, patient-specific therapies, and international business, with a strong emphasis on high-quality standards and innovative healthcare solutions.
In the first half of 2025, Medios AG reported a robust financial performance, with revenue increasing by 9.3% to €991.7 million and a significant rise in EBITDA by 71.8% to €42.2 million, driven by growth across all business segments and strategic acquisitions.
Key highlights include a remarkable increase in the International Business segment, which contributed significantly to revenue growth, and a successful public share buyback offer. The company’s earnings per share nearly doubled, reflecting strong profitability and strategic focus on high-margin sales.
Despite a decrease in cash flow from operating activities, the company’s financial position remains strong with a solid equity ratio and strategic investments in expanding its business operations. Medios AG’s management remains optimistic, expecting further revenue growth and an increase in EBITDA for the full year 2025, supported by organic growth and the integration of recent acquisitions.